The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: Are all the angiotensin receptor blockers equal?

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 2, 2007, Pages 191-205

  Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b   Athyros, Vasilios G ^a   Kakafika, Anna I ^a,b   Tziomalos, Konstantinos ^a   Liberopoulos, Evangelos N ^c   Florentin, Matilda ^a   Elisaf, Moses ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiotensin receptor blocker; Hypertension; Insulin resistance; Metabolic syndrome; Telmisartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FENOFIBRATE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; URIC ACID; VALSARTAN;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETOGENESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FOOD; FOOD DRUG INTERACTION; GLUCOSE METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; WEIGHT GAIN;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33846700554     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.2.191     Document Type: Review

References (205)

1. ALBERTI KG, ZIMMET PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. (1998) 15:539-553.
2. GRUNDY SM, CLEEMAN JI, DANIELS SR et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation (2005) 112:2735-2752.
3. KAKAFIKA AI, LIBEROPOULOS EN, KARAGIANNIS A, ATHYROS VG, MIKHAILIDIS DP: Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr. Vasc. Pharmacol. (2006) 4:175-183.
4. FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 287:356-359.
5. ATHYROS VG, BOULOUKOS VI, PEHLIVANIDIS AN et al.: The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes. Metab. (2005) 7:397-405.
6. AZIZI F, SALEHI P, ETEMADI A, ZAHEDI-ASL S: Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res. Clin. Pract. (2003) 61:29-37.
7. ISOMAA B, ALMGREN P, TUOMI T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 24:683-689.
8. LAKKA HM, LAAKSONEN DE, LAKKA TA et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA (2002) 288:2709-2716.
9. ATHYROS VG, GANOTAKIS ES, ELISAF M, MIKHAILIDIS DP: The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr. Med. Res. Opin. (2005) 21:1157-1159.
10. PARK YW, ZHU S, PALANIAPPAN L, HESHKA S, CARNETHON MR, HEYMSFIELD SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. (2003) 163:427-436.
11. ATHYROS VG, MIKHAILIDIS DP, PAPAGEORGIOU AA et al.: Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr. Med. Res. Opin. (2004) 20:1691-1701.
12. DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF M: Prevention and treatment of the metabolic syndrome. Angiology (2004) 55:589-612.
13. MILIONIS HJ, RIZOS E, GOUDEVENOS J, SEFERIADIS K, MIKHAILIDIS DP, ELISAF MS: Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 36:1372-1376.
14. BALKAU B, VERNAY M, MHAMDI L et al.: The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. (2003) 29:526-532.
15. SATTAR N, GAW A, SCHERBAKOVA O et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 108:414-419.
16. LIBEROPOULOS EN, TSOULI S, MIKHAILIDIS DP, ELISAF MS: Preventing Type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr. Drug Targets (2006) 7:211-228.
17. ECKEL RH, GRUNDY SM, ZIMMET PZ: The metabolic syndrome. Lancet (2005) 365:1415-1428.
18. GRUNDY SM: Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. (2004) 89:2595-2600.
19. SALTIEL AR, KAHN CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 414:799-806.
20. ANDERSON EA, MARK AL: Cardiovascular and sympathetic actions of insulin: the insulin hypothesis of hypertension revisited. Cardiovasc. Risk Factors (1993) 3:159-163.
21. STEINBERG HO, BRECHTEL G, JOHNSON A, FINEBERG N, BARON AD: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Invest. (1994) 94:1172-1179.
22. DEFRONZO RA, COOKE CR, ANDRES R, FALOONA GR, DAVIS PJ: The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest. (1975) 55:845-855.
23. TOOKE JE, HANNEMANN MM: Adverse endothelial function and the insulin resistance syndrome. J. Intern. Med. (2000) 247:425-431.
24. KURODA S, UZU T, FUJII T et al.: Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension. J. Hum. Hypertens. (1999) 13:257-262.
25. WELBORN TA, BRECKENRIDGE A, RUBINSTEIN AH, DOLLERY CT, FRASER TR: Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet (1966) 1:1336-1337.
26. BERGLUND G, LARSSON B, ANDERSSON O et al.: Body composition and glucose metabolism in hypertensive middle-aged males. Acta Med. Scand. (1976) 200:163-169.
27. FERRANNINI E, BUZZIGOLI G, BONADONNA R et al.: Insulin resistance in essential hypertension. N. Engl. J. Med. (1987) 317:350-357.
28. LENDER D, ARAUZ-PACHECO C, ADAMS-HUET B, RASKIN P: Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension (1997) 29:111-114.
29. LISSNER L, BENGTSSON C, LAPIDUS L, KRISTJANSSON K, WEDEL H: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension (1992) 20:797-801.
30. HAFFNER SM, FERRANNINI E, HAZUDA HP, STERN MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension (1992) 20:38-45.
31. FERRARI P, WEIDMANN P, SHAW S et al.: Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am. J. Med. (1991) 91:589-596.
32. ALLEMANN Y, HORBER FF, COLOMBO M et al.: Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet (1993) 341:327-331.
33. TAITTONEN L, UHARI M, NUUTINEN M, TURTINEN J, POKKA T, AKERBLOM HK: Insulin and blood pressure among healthy children. Cardiovascular risk in young Finns. Am. J. Hypertens. (1996) 9:194-199.
34. WOO J, COCKRAM CS, LAU E, CHAN A, SWAMINATHAN R: Association between insulin and blood pressure in a community population with normal glucose tolerance. J. Hum. Hypertens. (1992) 6:343-347.
35. FALKNER B, HULMAN S, KUSHNER H: Insulin-stimulated glucose utilization and borderline hypertension in young adult blacks. Hypertension (1993) 22:18-25.
36. TSURUTA M, HASHIMOTO R, ADACHI H, IMAIZUMI T, NOMURA G: Hyperinsulinaemia as a predictor of hypertension: an 11-year follow-up study in Japan. Hypertension (1996) 14:483-488.
37. REAVEN GM: Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metab. (2003) 88:2399-2403.
38. ARCARO G, CRETTI A, BALZANO S et al.: Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation (2002) 105:576-582.
39. TUCK ML, BOUNOUA F, ESLAMI P, NYBY MD, EGGENA P, CORRY DB: Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J. Hypertens. (2004) 22:1779-1785.
40. HAFFNER S, TAEGTMEYER H: Epidemic obesity and the metabolic syndrome. Circulation (2003) 108:1541-1545.
41. BARON AD, TARSHOBY M, HOOK G et al.: Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes (2000) 49:768-774.
42. KASHYAP SR, ROMAN LJ, LAMONT J et al.: Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of Type 2 diabetic subjects. J. Clin. Endocrinol. Metab. (2005) 90:1100-1105.
43. SAAD MF, LILLIOJA S, NYOMBA BL et al.: Racial differences in the relation between blood pressure and insulin resistance. N. Engl. J. Med. (1991) 324:733-739.
44. HAFFNER SM, D'AGOSTINO R, SAAD MF et al.: Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes (1996) 45:742-748.
45. DOWSE GK, COLLINS VR, ALBERTI KG et al.: Insulin and blood pressure levels are not independently related in Mauritians of Asian Indian, Creole or Chinese origin. The Mauritius Non-communicable Disease Study Group. J. Hypertens. (1993) 11:297-307.
46. TAPPY L, BOVET P, JEQUIER E, SHAMLAYE C, DARIOLI R, BURNAND B: Relationship of fasting serum insulin concentrations with blood pressure in a representative sample of the adult population of the Seychelles. Int. J. Obes. (1991) 15:669-675.
47. SAAD MF, REWERS M, SELBY J et al.: Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension (2004) 43:1324-1331.
48. REAVEN GM: Clinical review 43: Treatment of hypertension: focus on prevention of coronary heart disease. J. Clin. Endocrinol. Metab. (1993) 76:537-540.
49. LIBEROPOULOS EN, MIKHAILIDIS DP, ELISAF MS: Diagnosis and management of the metabolic syndrome in obesity. Obes. Rev. (2005) 6:283-296.
50. HEDLEY AA, OGDEN CL, JOHNSON CL, CARROLL MD, CURTIN LR, FLEGAL KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA (2004) 291:2847-2850.
51. PARADIS G, LAMBERT M, O'LOUGHLIN J et al.: Blood pressure and adiposity in children and adolescents. Circulation. (2004) 110:1832-1838.
52. KANNEL WB, GARRISON RJ, DANNENBERG AL: Secular blood pressure trends in normotensive persons: the Framingham study. Am. Heart J. (1993) 125:1154-1158.
53. HUANG Z, WILLETT WC, MANSON JE et al.: Body weight, weight change, and risk for hypertension in women. Ann. Intern. Med. (1998) 128:81-88.
54. MOKDAD AH, FORD ES, BOWMAN BA et al.: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 289:76-79.
55. SHARMA AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension (2004) 44:12-19.
56. HALL JE, BRANDS MW, HENEGAR JR: Mechanisms of hypertension and kidney disease in obesity. Ann. N. Y. Acad. Sci. (1999) 892:91-107.
57. LANDSBERG L: Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J. Hypertens. (2001) 19:523-528.
58. GORZELNIAK K, ENGELI S, JANKE J, LUFT FC, SHARMA AM: Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J. Hypertens. (2002) 20:965-973.
59. EHRHART-BORNSTEIN M, LAMOUNIER-ZEPTER V, SCHRAVEN A et al.: Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Aacad. Sci. USA (2003) 100:14211-14216.
60. CORREIA ML, HAYNES WG: Obesity-related hypertension: is there a role for selective leptin resistance? Curr. Hypertens. Rep. (2004) 6:230-235.
61. SOWERS JR, FROHLICH ED: Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med. Clin. North Am. (2004) 88:63-82.
62. NIELSEN S, GUO Z, JOHNSON CM, HENSRUD DD, JENSEN MD: Splanchnic lipolysis in human obesity. J. Clin. Invest. (2004) 113:1582-1588.
63. PERTICONE F, CERAVOLO R, CANDIGLIOTA M et al.: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes (2001) 50:159-165.
64. CARDILLO C, CAMPIA U, IANTORNO M, PANZA JA: Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension (2004) 43:36-40.
65. WILDMAN RP, FARHAT GN, PATEL AS et al.: Weight change is associated with change in arterial stiffness among healthy young adults. Hypertension (2005) 45:187-192.
66. DE JONGH RT, SERNE EH, IJZERMAN RG, DE VRIES G, STEHOUWER CD: Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation (2004) 109:2529-2535.
67. KURTZ TW, GARDNER DG: Transcription-modulating drugs: a new frontier in the treatment of essential hypertension. Hypertension (1998) 32:380-386.
68. OGIHARA T, ASANO T, ANDO K et al.: Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension (2002) 40:872-879.
69. VELLOSO LA, FOLLI F, SUN XJ, WHITE MF, SAAD MJ, KAHN CR: Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. USA (1996) 93:12490-12495.
70. FOLLI F, SAAD MJ, VELLOSO L et al.: Crosstalk between insulin and angiotensin II signalling systems. Exp. Clin. Endocrinol. Diabetes (1999) 107:133-139.
71. FOLLI F, KAHN CR, HANSEN H, BOUCHIE JL, FEENER EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J. Clin. Invest. (1997) 100:2158-2169.
72. PAOLISSO G, TAGLIAMONTE MR, GAMBARDELLA A et al.: Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J. Hum. Hypertens. (1997) 11:307-312.
73. NAWANO M, ANAI M, FUNAKI M et al.: Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism (1999) 48:1248-1255.
74. ANDREOZZI F, LARATTA E, SCIACQUA A, PERTICONE F, SESTI G: Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ. Res. (2004) 94:1211-1218.
75. KRUTZFELDT J, RAASCH W, KLEIN HH: Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch. Pharmacol (2000) 362:1-6.
76. SHIUCHI T, IWAI M, LI HS et al.: Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension (2004) 43:1003-1010.
77. JANKE J, ENGELI S, GORZELNIAK K, LUFT FC, SHARMA AM: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin Type 1 receptors. Diabetes (2002) 51:1699-1707.
78. SHARMA AM, JANKE J, GORZELNIAK K, ENGELI S, LUFT FC: Angiotensin blockade prevents Type 2 diabetes by formation of fat cells. Hypertension (2002) 40:609-611.
79. FLISER D, DIKOW R, DEMUKAJ S, RITZ E: Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. J. Am. Soc. Nephrol. (2000) 11:2001-2006.
80. CARLSSON PO, BERNE C, JANSSON L: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia (1998) 41:127-133.
81. BERNOBICH E, DE ANGELIS L, LERIN C, BELLINI G: The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs (2002) 62:1295-1314.
82. MCFARLANE SI, KUMAR A, SOWERS JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. (2003) 91:30H-37H.
83. GILLESPIE EL, WHITE CM, KARDAS M, LINDBERG M, COLEMAN CI: The impact of ACE inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care (2005) 28:2261-2266.
84. HANSSON L, LINDHOLM LH, EKBOM T et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 354:1751-1756.
85. HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (1999) 353:611-616.
86. YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
87. YUSUF S, GERSTEIN H, HOOGWERF B et al.; HOPE Study Investigators: Ramipril and the development of diabetes. JAMA (2001) 286:1882-1885.
88. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288:2981-2997.
89. NO AUTHORS LISTED: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 20:1183-1197.
90. THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. (1992) 327:685-691.
91. VERMES E, DUCHARME A, BOURASSA MG, LESSARD M, WHITE M, TARDIF JC: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation (2003) 107:1291-1296.
92. BRAUNWALD E, DOMANSKI MJ, FOWLER SE et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. (2004) 351:2058-2068.
93. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
94. LINDHOLM LH, IBSEN H, BORCH-JOHNSEN K et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens. (2002) 20:1879-1886.
95. BENGTSSON C, BLOHME G, LAPIDUS L, LISSNER L, LUNDGREN H: Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of women in Gothenburg, Sweden. J. Intern. Med. (1992) 231:583-588.
96. MYKKANEN L, KUUSISTO J, PYORALA K, LAAKSO M, HAFFNER SM: Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J. Hypertens. (1994) 12:1425-1432.
97. SAMUELSSON O, HEDNER T, BERGLUND G, PERSSON B, ANDERSSON OK, WILHELMSEN L: Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective β-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J. Hum. Hypertens. (1994) 8:257-263.
98. GRESS TW, NIETO FJ, SHAHAR E, WOFFORD MR, BRANCATI FL: Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med. (2000) 342:905-912.
99. JULIUS S, KJELDSEN SE, WEBER M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet (2004) 363:2022-2031.
100. LINDHOLM LH, PERSSON M, ALAUPOVIC P, CARLBERG B, SVENSSON A, SAMUELSSON O: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens. (2003) 21:1563-1574.
101. GRASSI G, SERAVALLE G, DELL'ORO R et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J. Hypertens. (2003) 21:1761-1769.
102. LITHELL H, HANSSON L, SKOOG I et al.: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. (2003) 21:875-886.
103. PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 362:759-766.
104. YUSUF S, PFEFFER MA, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet (2003) 362:777-781.
105. MCMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-771.
106. GRANGER CB, MCMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772-776
107. VERDECCHIA P, REBOLDI G, ANGELI F et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 43:963-969.
108. SCHEEN AJ: Prevention of Type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs (2004) 64:2537-2565.
109. SONG JC, WHITE CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy (2000) 20:130-139.
110. KURTZ TW, PRAVENEC M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J. Hypertens. (2004) 22:2253-2261.
111. PERSHADSINGH HA: Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ. Int. J. Biochem. Cell Biol. (2006) 38:766-781.
112. GOA KL, WAGSTAFF AJ: Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs (1996) 51:820-845.
113. NAKASHIMA M, UEMATSU T, KOSUGE K, KANAMARU M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. (1992) 42:333-335.
114. BURNIER M, RUTSCHMANN B, NUSSBERGER J et al.: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. (1993) 22:339-347.
115. FAUVEL JP, VELON S, BERRA N et al.: Effects of losartan on renal function in patients with essential hypertension. J. Cardiovasc. Pharmacol. (1996) 28:259-263.
116. SWEET CS, BRADSTREET DC, BERMAN RS, JALLARD N, SAENZ A, WEIDLER DJ: Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am. J. Hypertens. (1994) 7:1035-1040.
117. ROCH-RAMEL F, GUISAN B, DIEZI J: Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J. Pharmacol. Exp. Ther. (1997) 280:839-845.
118. ROCH-RAMEL F, WERNER D, GUISAN B: Urate transport in brush-border membrane of human kidney. Am. J. Physiol. (1994) 266:F797-F805.
119. CANNON PJ, STASON WB, DEMARTINI FE, SOMMERS SC, LARAGH JH: Hyperuricemia in primary and renal hypertension. N. Engl. J. Med. (1966) 275:457-464.
120. IWANAGA T, SATO M, MAEDA T, OGIHARA T, TAMAI I: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter URAT1. Pharmacol. Exp. Ther. (2006) Epub ahead of print.
121. LEHTO S, NISKANEN L, RONNEMAA T, LAAKSO M: Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke (1998) 29:635-639.
122. MAZZA A, PESSINA AC, PAVEI A, SCARPA R, TIKHONOFF V, CASIGLIA E: Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly. Eur. J. Epidemiol. (2001) 17:1097-1104.
123. KAHN HA, MEDALIE JH, NEUFELD HN, RISS E, GOLDBOURT U: The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am. Heart J. (1972) 84:171-182.
124. SELBY JV, FRIEDMAN GD, QUESENBERRY CP Jr: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am. J. Epidemiol. (1990) 131:1017-1027.
125. JOSSA F, FARINARO E, PANICO S et al.: Serum uric acid and hypertension: the Olivetti heart study. J. Hum. Hypertens. (1994) 8:677-681.
126. ISEKI K, OSHIRO S, TOZAWA M, ISEKI C, IKEMIYA Y, TAKISHITA S: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens. Res. (2001) 24:691-697.
127. ALDERMAN M, AIYER KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. (2004) 20:369-379.
128. QUINONES GALVAN A, NATALI A, BALDI S et al.: Effect of insulin on uric acid excretion in humans. Am. J. Physiol. (1995) 268:E1-E15.
129. MODAN M, HALKIN H, KARASIK A, LUSKY A: Elevated serum uric acid-a facet of hyperinsulinaemia. Diabetologia (1987) 30:713-718.
130. NAKAGAWA T, HU H, ZHARIKOV S et al.: A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. (2006) 290:F625-F631.
131. DASKALOPOULOU SS, TZOVARAS V, MIKHAILIDIS DP, ELISAF M: Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr. Pharm. Des. (2005) 11:4161-4175.
132. MESSERLI FH, FROHLICH ED, DRESLINSKI GR, SUAREZ DH, ARISTIMUNO GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann. Intern. Med. (1980) 93:817-821.
133. PUIG JG, RUILOPE LM: Uric acid as a cardiovascular risk factor in arterial hypertension. J. Hypertens. (1999) 17:869-872.
134. FRIEDL HP, TILL GO, TRENTZ O, WARD PA: Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients. Klin. Wochenschr. (1991) 69:1109-1112.
135. TINAHONES JF, PEREZ-LINDON G, C-SORIGUER FJ, PAREJA A, SANCHEZ-GUIJO P, COLLANTES E: Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J. Clin. Endocrinol. Metab. (1997) 82:1188-1191.
136. VUORINEN-MARKKOLA H, YKI-JARVINEN H: Hyperuricemia and insulin resistance. J. Clin. Endocrinol. Metab. (1994) 78:25-29.
137. FOX IH, JOHN D, DEBRUYNE S, DWOSH I, MARLISS EB: Hyperuricemia and hypertriglyceridemia: metabolic basis for the association. Metabolism (1985) 34:741-746.
138. GIACOMELLO A, DI SCIASCIO N, QUARATINO CP: Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism (1997) 46:1085-1089.
139. CLAUSEN JO, BORCH-JOHNSEN K, IBSEN H, PEDERSEN O: Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur. J. Endocrinol. (1998) 138:63-69.
140. CHEN J, MUNTNER P, HAMM LL et al.: The metabolic syndrome and chronic kidney disease in US adults. Ann. Intern. Med. (2004) 140:167-174.
141. NELSON RG, BENNETT PH, BECK GJ et al.: Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N. Engl. J. Med. (1996) 335:1636-1642.
142. HUMPHREY LL, BALLARD DJ, FROHNERT PP, CHU CP, O'FALLON WM, PALUMBO PJ: Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann. Intern. Med. (1989) 111:788-796.
143. WHELTON PK, PERNEGER TV, HE J, KLAG MJ: The role of blood pressure as a risk factor for renal disease: a review of the epidemiologic evidence. J. Hum. Hypertens. (1996) 10:683-689.
144. PERNEGER TV, NIETO FJ, WHELTON PK, KLAG MJ, COMSTOCK GW, SZKLO M: A prospective study of blood pressure and serum creatinine. Results from the 'Clue' study and the ARIC study. JAMA (1993) 269:488-493.
145. KOPPLE JD, GREENE T, CHUMLEA WC et al.: Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int. (2000) 57:1688-1703.
146. ISEKI K, IKEMIYA Y, INOUE T, ISEKI C, KINJO K, TAKISHITA S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am. J. Kidney Dis. (2004) 44:642-650.
147. LIESE AD, HENSE HW, LOWEL H, DORING A, TIETZE M, KEIL U: Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology (1999) 10:391-397.
148. VERDECCHIA P, SCHILLACI G, REBOLDI G, SANTEUSANIO F, PORCELLATI C, BRUNETTI P: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension (2000) 36:1072-1078.
149. FANG J, ALDERMAN MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA (2000) 283:2404-2410.
150. ALDERMAN MH, COHEN H, MADHAVAN S, KIVLIGHN S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension (1999) 34:144-150.
151. JOHNSON RJ, KANG DH, FEIG D et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 41:1183-1190.
152. DASKALOPOULOU SS, ATHYROS VG, ELISAF M, MIKHAILIDIS DP: Uric acid levels and vascular disease. Curr. Med. Res. Opin. (2004) 20:951-954.
153. TSOULI SG, LIBEROPOULOS EN, MIKHAILIDIS DP, ATHYROS VG, ELISAF MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 55:1293-1301.
154. MIMRAN A, RUILOPE L, KERWIN L et al.: A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J. Hum. Hypertens. (1998) 12:203-208.
155. ELLIOTT WJ, CALHOUN DA, DELUCCA PT, GAZDICK LP, KERNS DE, ZELDIN RK: Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin. Ther. (2001) 23:1166-1179.
156. GONZALEZ-ORTIZ M, MORA-MARTINEZ JM, MARTINEZ-ABUNDIS E, BALCAZAR-MUNOZ BR: Effect of valsartan on renal handling of uric acid in healthy subjects. J. Nephrol. (2000) 13:126-128.
157. MALMQVIST K, KAHAN T, DAHL M: Angiotensin II Type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am. J. Hypertens. (2000) 13:504-511.
158. PUIG JG, TORRES R, RUILOPE LM: AT1 blockers and uric acid metabolism: are there relevant differences? J. Hypertens. (2002) 20:S29-S31.
159. ILSON BE, MARTIN DE, BOIKE SC, JORKASKY DK: The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J. Clin. Pharmacol. (1998) 38:437-441.
160. SOFFER BA, WRIGHT JT JR, PRATT JH, WIENS B, GOLDBERG AI, SWEET CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 26:112-117.
161. OPARIL S, AURUP P, SNAVELY D, GOLDBERG A: Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am. J. Cardiol. (2001) 87:721-726.
162. OWENS P, KELLY L, NALLEN R, RYAN D, FITZGERALD D, O'BRIEN E: Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide - a randomized controlled trial. J. Hypertens. (2000) 18:339-345.
163. NIKAS S, RIZOS E, MILIONIS H et al.: The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide. J. Renin Angiotensin Aldosterone Syst. (2000) 1:289-291.
164. MILIONIS HJ, NIKAS S, ELISAF MS: Effects of losartan/diuretic combination treatment on serum uric acid levels in hypertensive patients. Am. J. Cardiol. (2001) 88:1084.
165. RAYNER BL, TRINDER YA, BAINES D, ISAACS S, OPIE LH: Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am. J. Hypertens. (2006) 19:208-213.
166. DANG A, ZHANG Y, LIU G, CHEN G, SONG W, WANG B: Effects of losartan and irbesartan on serum uric acid in hypertensive patients with
167. LIBEROPOULOS E, CHRISTIDES D, ELISAF M: Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J. Hypertens. (2002) 20:347.
168. ELISAF M, TSIMICHODIMOS V, BAIRAKTARI E, SIAMOPOULOS KC: Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J. Cardiovasc. Pharmacol. (1999) 34:60-63.
169. HOIEGGEN A, ALDERMAN MH, KJELDSEN SE et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. (2004) 65:1041-1049.
170. DASKALOPOULOU SS, ATHYROS VG, ELISAF M, MIKHAILIDIS D: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. (2004) 66:1714-1715.
171. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582-1587.
172. DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360:752-760.
173. BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
174. COHN JN, TOGNONI G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345:1667-1675.
175. PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
176. VIBERTI G, WHEELDON NM: Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 106:672-678.
177. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, GOMIS R, ANDERSEN S, ARNER P: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. (2001) 345:870-878.
178. LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
179. PUIG JG, LOPEZ MA, BUESO TS, BERNARDINO JI, JIMENEZ RT: Clinical profile of eprosartan. Cardiovasc. Drugs Ther. (2002) 16:543-549.
180. HEUSSER K, VITKOVSKY J, RAASCH W, SCHMIEDER RE, SCHOBEL HP: Elevation of sympathetic activity by eprosartan in young male subjects. Am. J. Hypertens. (2003) 16:658-664.
181. SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36:1218-1226.
182. LAEIS P, PUCHLER K, KIRCH W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. (2001) 19(Suppl. 1):S21-S32.
183. OPARIL S, SILFANI TN, WALKER JF: Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am. J. Hypertens. (2005) 18(2 Pt 1):287-294.
184. MCCLELLAN KJ, MARKHAM A: Telmisartan. Drugs (1998) 56:1039-1044.
185. BARNETT AH, BAIN SC, BOUTER P et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. (2004) 351:1952-1961.
186. BENSON SC, PERSHADSINGH HA, HO CI et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension (2004) 43:993-1002.
187. SCHUPP M, CLEMENZ M, GINESTE R et al.: Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes (2005) 54:3442-3452.
188. SCHUPP M, JANKE J, CLASEN R, UNGER T, KINTSCHER U: Angiotensin Type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ, activity. Circulation (2004) 109:2054-2057.
189. KURTZ TW: New treatment strategies for patients with hypertension and insulin resistance. Am. J. Med. (2006) 119(Suppl. 1):S24-S30.
190. CLASEN R, SCHUPP M, FORYST-LUDWIG A et al.: PPARγ-activating angiotensin type- 1 receptor blockers induce adiponectin. Hypertension (2005) 46:137-143.
191. KINTSCHER U, UNGER T: Vascular protection in diabetes: a pharmacological view of angiotensin II Type 1 receptor blockers. Acta Diabetol. (2005) 42:S26-S32.
192. YAMAGISHI S, TAKEUCHI M: Telmisartan is a promising cardiometabolic sartan due to its unique PPARγ,-inducing property. Med. Hypotheses (2005) 64:476-478.
193. TAKANO H, HASEGAWA H, ZOU Y, KOMURO I: Pleiotropic actions of PPARγ activators thiazolidinediones in cardiovascular diseases. Curr. Pharm. Des. (2004) 10:2779-2786.
194. MARX N, DUEZ H, FRUCHART JC, STAELS B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. (2004) 94:1168-1178.
195. MARSHALL TG, LEE RE, MARSHALL FE: Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor. Biol. Med. Model. (2006) 3:1.
196. PERSHADSINGH HA, KURTZ TW: Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care. (2004) 27:1015.
197. MICHEL MC, BOHNER H, KOSTER J, SCHAFERS R, HEEMANN U: Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. (2004) 27:335-344.
198. DEROSA G, RAGONESI PD, MUGELLINI A, CICCARELLI L, FOGARI R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, Type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. (2004) 27:457-464.
199. HONJO S, NICHI Y, WADA Y, HAMAMOTO Y, KOSHIYAMA H: Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care (2005) 28:498.
200. MIURA Y, YAMAMOTO N, TSUNEKAWA S et al.: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with Type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care (2005) 28:757-758.
201. DREAM Trial Investigators; BOSCH J, YUSUF S, GERSTEIN HC et al.: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. (2006) 355:1551-1562.
202. GERSTEIN HC, YUSUF S, BOSCH J et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 368:1096-1105.
203. TEO K, YUSUF S, SLEIGHT P et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. (2004) 148:52-61.
204. SLEIGHT P: The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol. (2005) 42(Suppl. 1):S50-S56.
205. TSOULI SG, LIBEROPOULOS EN, KIORTSIS DN, MIKHAILIDIS DP, ELISAF MS: Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. J. Cardiovasc. Pharmacol. Ther. (2006) 11:1-15.